International โบ Comparison ยท Last reviewed 2026-05-16
International comparison
Policy and current status of adolescent gender care in nine countries, in one overview. The last column links to the dossier where each row is substantiated.
| Country | Key document | GnRHa < 18 | CSH < 18 | Required setting | Dossier |
|---|---|---|---|---|---|
| Netherlands | Quality Standard Transgender Care โ Somatic (2019); Health Council advice (2026) | Permitted | Permitted from 15โ16 under conditions | Clinical care | current status NL |
| UK | Cass Review 2024 + NHS England 2024 | Research only | Restrictive | Research / specialist hubs | UK ยท Cass |
| Sweden | SBU 2022 + Socialstyrelsen 2022 | Research setting or exceptional cases | Research setting or exceptional cases | Research | Sweden ยท SBU |
| Finland | COHERE 2020 | Selective, psychotherapy first | Selective | Two specialised centres | Finland ยท COHERE |
| Norway | Ukom 2023 (recommendations) | Recommended to be defined as experimental treatment | Recommended to be defined as experimental treatment | Revision of the national guideline recommended | Norway |
| Denmark | Sundhedsstyrelsen guidance (2018) | Possible from Tanner stage IIโIII | From about age 15โ16 | National service | Denmark |
| Germany | AWMF S2k guideline (registry no. 028-014) | Permitted | Permitted | Guideline-based care | Germany |
| US (federal) | Endocrine Society 2017 + AAP 2018 | Permitted (varies by state) | Permitted (varies by state) | Clinical care | US |
| US (states with bans, e.g. Tennessee) | State laws; Supreme Court, Skrmetti (18 June 2025) | Prohibited where bans apply | Prohibited where bans apply | n/a | Skrmetti |
| Australia | RCH Melbourne SoC 2018 | Varies by state (Queensland: paused) | Varies by state (Queensland: paused) | Clinical care | Australia |
What the table shows
Two groups are recognisable: (a) countries where medical treatment of minors remains available within existing guidelines (Netherlands, Germany, part of the US) and (b) countries or states that have restricted it (UK, Sweden, Finland, Queensland, part of the US), while Norway's Ukom has recommended defining the treatment as experimental. Between 2020 and 2025 several of them tightened their policy: Finland (COHERE, June 2020), Sweden (Socialstyrelsen, 2022), the UK (NHS England, 2024) and Queensland (2025). The Dutch Health Council notes that in Germany, Austria, Switzerland, France and Poland treatment has recently been anchored more firmly in guidelines (source).
Critical note
Not every revision rests on the same kind of evidence review: Sweden (SBU 2022) and England (the York reviews for the Cass Review) had the evidence reviewed systematically, whereas Norway's Ukom noted that Norway has no systematic knowledge summary and recommended that one be made (source). In June 2026 the Dutch Health Council advised against changing Dutch care, while rating the strength of the evidence as "low to very low" and concluding that cognition, fertility and long-term effects are insufficiently studied (source).
See also
- Worldwide status 2025 โ more extensive narrative discussion.
- International spread โ historical adoption.
- Guidelines international โ primary documents.
- Evaluations โ overview โ a dossier per evaluation.